



- (51) International Patent Classification:
C07D 401/14 (2006.01)
- (21) International Application Number:
PCT/US2015/016928
- (22) International Filing Date:
20 February 2015 (20.02.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/942,956 21 February 2014 (21.02.2014) US
- (71) Applicant: **FROST BIOLOGIC, INC.** [US/US]; 2401
So. Foothill Road, Salt Lake City, Utah 84109 (US).
- (72) Inventor: **SIDDIQUI-JAIN, Adam**; 11643 South Jordan
Farms Rd., South Jordan, UT 84095 (US).
- (74) Agents: **MARSHALL, Ryan, L.** et al.; Brinks Gilson &
Lione, P.O. Box 10087, Chicago, IL 60610 (US).
- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*

- (54) Title: ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS



- (57) Abstract: Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of Formula I where Ar, R⁵, R⁶, R⁸, R⁹, R¹¹, X¹, and X² are as defined herein, as compounds for treatment and prevention of cancer and proliferative diseases and disorders.